Generation of WT and PPT1 KO palmitome and proteome expands the repertoire of known palmitoylated proteins in the brain. by Erica L. Gorenberg (12329728)

“…A total of 15 palmitoylated proteins are significantly differentially expressed in whole brain (3 decreased, including PPT1; 12 increased; 1.5-fold, <i>p</i> < 0.05; blue lines). …”

Ovarian reaction to acute estrogen exposure. by Clémentine Chalmey (5657233)

“…A false-color heatmap shows cases of increasing, decreasing, detectable (but without differential expression) and undetectable transcript signal intensities across the replicates for different total ovary samples at the time points given (top). …”

(A) Profile of mean-squared error of elastic-net regression for various values of lambda. by Chan C. Whiting (773096)

“…Thus, for example, the estimated age increases by approximately 1.6 years for every unit increase in absolute monocyte count (the analyte with the largest positive coefficient), holding all other values constant; and decreases by approximately 4.5 years for every unit increase in naïve CD8+ T cells (the analyte with the largest negative coefficient). …”

Table_1_COVI-Prim international: Similarities and discrepancies in the way general practices from seven different countries coped with the COVID-19 pandemic.DOCX by Andrea Siebenhofer (3558623)

“…A decrease in the number of patient contacts (5.7, 95% CI 5.4–5.9), the perception of risk (5.3 95% CI 4.9–5.6), the provision of information to GPs (4.9, 95% CI 4.6–5.2), their testing of suspected cases (3.7, 95% CI 3.4–3.9) and their preparedness to face a pandemic (mean: 3.5; 95% CI 3.2–3.7) were rated as moderate. …”

Table_2_COVI-Prim international: Similarities and discrepancies in the way general practices from seven different countries coped with the COVID-19 pandemic.DOCX by Andrea Siebenhofer (3558623)

“…A decrease in the number of patient contacts (5.7, 95% CI 5.4–5.9), the perception of risk (5.3 95% CI 4.9–5.6), the provision of information to GPs (4.9, 95% CI 4.6–5.2), their testing of suspected cases (3.7, 95% CI 3.4–3.9) and their preparedness to face a pandemic (mean: 3.5; 95% CI 3.2–3.7) were rated as moderate. …”

Table_1_COVI-Prim international: Similarities and discrepancies in the way general practices from seven different countries coped with the COVID-19 pandemic.DOCX by Andrea Siebenhofer (3558623)

“…A decrease in the number of patient contacts (5.7, 95% CI 5.4–5.9), the perception of risk (5.3 95% CI 4.9–5.6), the provision of information to GPs (4.9, 95% CI 4.6–5.2), their testing of suspected cases (3.7, 95% CI 3.4–3.9) and their preparedness to face a pandemic (mean: 3.5; 95% CI 3.2–3.7) were rated as moderate. …”

Table_2_COVI-Prim international: Similarities and discrepancies in the way general practices from seven different countries coped with the COVID-19 pandemic.DOCX by Andrea Siebenhofer (3558623)

“…A decrease in the number of patient contacts (5.7, 95% CI 5.4–5.9), the perception of risk (5.3 95% CI 4.9–5.6), the provision of information to GPs (4.9, 95% CI 4.6–5.2), their testing of suspected cases (3.7, 95% CI 3.4–3.9) and their preparedness to face a pandemic (mean: 3.5; 95% CI 3.2–3.7) were rated as moderate. …”

Supplementary Material for: Urinary Biomarkers of Tubular Health and Risk for Kidney Function Decline or Mortality in Diabetes by Chen T.K. (14350107)

“…Methods: We examined associations of five urinary biomarkers of tubular injury and repair (NGAL, KIM-1, IL-18, MCP-1, YKL-40) with kidney function decline (first occurrence of a decrease in eGFR≥30 ml/min/1.73 m2 if randomization eGFR≥60 or ≥50% if randomization eGFR<60; ESKD) and all-cause mortality among 1,135 VA NEPHRON-D trial participants with baseline UACR ≥300 mg/g and available urine samples. …”

Supplementary Material for: Urinary Biomarkers of Tubular Health and Risk for Kidney Function Decline or Mortality in Diabetes by Chen T.K. (14350107)

“…Methods: We examined associations of five urinary biomarkers of tubular injury and repair (NGAL, KIM-1, IL-18, MCP-1, YKL-40) with kidney function decline (first occurrence of a decrease in eGFR≥30 ml/min/1.73 m2 if randomization eGFR≥60 or ≥50% if randomization eGFR<60; ESKD) and all-cause mortality among 1,135 VA NEPHRON-D trial participants with baseline UACR ≥300 mg/g and available urine samples. …”

Supplementary Material for: Urinary Biomarkers of Tubular Health and Risk for Kidney Function Decline or Mortality in Diabetes by Chen T.K. (14350107)

“…Methods: We examined associations of five urinary biomarkers of tubular injury and repair (NGAL, KIM-1, IL-18, MCP-1, YKL-40) with kidney function decline (first occurrence of a decrease in eGFR≥30 ml/min/1.73 m2 if randomization eGFR≥60 or ≥50% if randomization eGFR<60; ESKD) and all-cause mortality among 1,135 VA NEPHRON-D trial participants with baseline UACR ≥300 mg/g and available urine samples. …”

Supplementary Material for: Urinary Biomarkers of Tubular Health and Risk for Kidney Function Decline or Mortality in Diabetes by Chen T.K. (14350107)

“…Methods: We examined associations of five urinary biomarkers of tubular injury and repair (NGAL, KIM-1, IL-18, MCP-1, YKL-40) with kidney function decline (first occurrence of a decrease in eGFR≥30 ml/min/1.73 m2 if randomization eGFR≥60 or ≥50% if randomization eGFR<60; ESKD) and all-cause mortality among 1,135 VA NEPHRON-D trial participants with baseline UACR ≥300 mg/g and available urine samples. …”

Supplementary Material for: Urinary Biomarkers of Tubular Health and Risk for Kidney Function Decline or Mortality in Diabetes by Chen T.K. (14350107)

“…Methods: We examined associations of five urinary biomarkers of tubular injury and repair (NGAL, KIM-1, IL-18, MCP-1, YKL-40) with kidney function decline (first occurrence of a decrease in eGFR≥30 ml/min/1.73 m2 if randomization eGFR≥60 or ≥50% if randomization eGFR<60; ESKD) and all-cause mortality among 1,135 VA NEPHRON-D trial participants with baseline UACR ≥300 mg/g and available urine samples. …”

Supplementary Material for: Urinary Biomarkers of Tubular Health and Risk for Kidney Function Decline or Mortality in Diabetes by Chen T.K. (14350107)

“…Methods: We examined associations of five urinary biomarkers of tubular injury and repair (NGAL, KIM-1, IL-18, MCP-1, YKL-40) with kidney function decline (first occurrence of a decrease in eGFR≥30 ml/min/1.73 m2 if randomization eGFR≥60 or ≥50% if randomization eGFR<60; ESKD) and all-cause mortality among 1,135 VA NEPHRON-D trial participants with baseline UACR ≥300 mg/g and available urine samples. …”

Supplementary Material for: Urinary Biomarkers of Tubular Health and Risk for Kidney Function Decline or Mortality in Diabetes by Chen T.K. (14350107)

“…Methods: We examined associations of five urinary biomarkers of tubular injury and repair (NGAL, KIM-1, IL-18, MCP-1, YKL-40) with kidney function decline (first occurrence of a decrease in eGFR≥30 ml/min/1.73 m2 if randomization eGFR≥60 or ≥50% if randomization eGFR<60; ESKD) and all-cause mortality among 1,135 VA NEPHRON-D trial participants with baseline UACR ≥300 mg/g and available urine samples. …”

Supplementary Material for: Urinary Biomarkers of Tubular Health and Risk for Kidney Function Decline or Mortality in Diabetes by Chen T.K. (14350107)

“…Methods: We examined associations of five urinary biomarkers of tubular injury and repair (NGAL, KIM-1, IL-18, MCP-1, YKL-40) with kidney function decline (first occurrence of a decrease in eGFR≥30 ml/min/1.73 m2 if randomization eGFR≥60 or ≥50% if randomization eGFR<60; ESKD) and all-cause mortality among 1,135 VA NEPHRON-D trial participants with baseline UACR ≥300 mg/g and available urine samples. …”

Supplementary Material for: Urinary Biomarkers of Tubular Health and Risk for Kidney Function Decline or Mortality in Diabetes by Chen T.K. (14350107)

“…Methods: We examined associations of five urinary biomarkers of tubular injury and repair (NGAL, KIM-1, IL-18, MCP-1, YKL-40) with kidney function decline (first occurrence of a decrease in eGFR≥30 ml/min/1.73 m2 if randomization eGFR≥60 or ≥50% if randomization eGFR<60; ESKD) and all-cause mortality among 1,135 VA NEPHRON-D trial participants with baseline UACR ≥300 mg/g and available urine samples. …”

Supplementary Material for: Urinary Biomarkers of Tubular Health and Risk for Kidney Function Decline or Mortality in Diabetes by Chen T.K. (14350107)

“…Methods: We examined associations of five urinary biomarkers of tubular injury and repair (NGAL, KIM-1, IL-18, MCP-1, YKL-40) with kidney function decline (first occurrence of a decrease in eGFR≥30 ml/min/1.73 m2 if randomization eGFR≥60 or ≥50% if randomization eGFR<60; ESKD) and all-cause mortality among 1,135 VA NEPHRON-D trial participants with baseline UACR ≥300 mg/g and available urine samples. …”

Supplementary Material for: Urinary Biomarkers of Tubular Health and Risk for Kidney Function Decline or Mortality in Diabetes by Chen T.K. (14350107)

“…Methods: We examined associations of five urinary biomarkers of tubular injury and repair (NGAL, KIM-1, IL-18, MCP-1, YKL-40) with kidney function decline (first occurrence of a decrease in eGFR≥30 ml/min/1.73 m2 if randomization eGFR≥60 or ≥50% if randomization eGFR<60; ESKD) and all-cause mortality among 1,135 VA NEPHRON-D trial participants with baseline UACR ≥300 mg/g and available urine samples. …”

Supplementary Material for: Urinary Biomarkers of Tubular Health and Risk for Kidney Function Decline or Mortality in Diabetes by Chen T.K. (14350107)

“…Methods: We examined associations of five urinary biomarkers of tubular injury and repair (NGAL, KIM-1, IL-18, MCP-1, YKL-40) with kidney function decline (first occurrence of a decrease in eGFR≥30 ml/min/1.73 m2 if randomization eGFR≥60 or ≥50% if randomization eGFR<60; ESKD) and all-cause mortality among 1,135 VA NEPHRON-D trial participants with baseline UACR ≥300 mg/g and available urine samples. …”

Supplementary Material for: Urinary Biomarkers of Tubular Health and Risk for Kidney Function Decline or Mortality in Diabetes by Chen T.K. (14350107)

“…Methods: We examined associations of five urinary biomarkers of tubular injury and repair (NGAL, KIM-1, IL-18, MCP-1, YKL-40) with kidney function decline (first occurrence of a decrease in eGFR≥30 ml/min/1.73 m2 if randomization eGFR≥60 or ≥50% if randomization eGFR<60; ESKD) and all-cause mortality among 1,135 VA NEPHRON-D trial participants with baseline UACR ≥300 mg/g and available urine samples. …”